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Abstract 
Hydroxyurea is the standard treatment in high risk patients with polycythemia vera. Yet, estimates of its 
effect in terms of clinical outcomes (thrombosis, bleeding, hematological transformations and mortality) are 
lacking. We performed a meta-analysis to determine the absolute risk of events in contemporary patients 
under hydroxyurea treatment. 
We searched for relevant articles or abstracts in the following databases: Medline, EMBASE, 
clinicaltrials.gov, WHO International Clinical Trials Registry, LILACS. 
Sixteen studies published from 2008 to 2018 reporting number of events using WHO diagnosis for 
polycythemia vera were selected. Through a random effect logistic model, incidences, study heterogeneity 
and confounder effects were estimated for each outcome at different follow-ups.   
Overall, 3,236 patients were analyzed. While incidences of thrombosis and acute myeloid leukemia were 
stable over time, mortality and myelofibrosis varied depending on follow-up duration. 
Thrombosis rates were 1·9, 3·6 and 6·8% persons/year at median ages 60, 70 and 80 respectively. Higher 
incidence of arterial events was predicted by previous cardiovascular complication. Leukemic transformation 
incidence was 0·4% persons/year. Incidence of transformation to myelofibrosis and mortality were 
significantly dependent on age and follow-up duration. For myelofibrosis, rates were 5·0 at 5 year and 33·7% 
at 10 years; overall mortality was 12·6% and 56·2% at 5 and 10 years respectively. 
In conclusion, we provide reliable risk estimates for the main outcomes in polycythemia vera patients under 
hydroxyurea treatment. These findings can help design comparative clinical trials with new cytoreductive 
drugs and prove the feasibility of using hard endpoints for efficacy, such as major thrombosis.  
Introduction 
Polycythemia vera (PV) is a myeloproliferative neoplasm (MPN) characterized by clonal proliferation of the 
erythroid, myeloid, and megakaryocyte lineages. This disease is recognized for its distinct molecular profile 
(JAKV617F mutation) and has a characteristic natural history marked by high frequency of thrombosis and a 
tendency to transform into acute myelogenous leukemia (AML) or myelofibrosis (MF). The first step in 
approaching an individual patient with PV is to identify the potential risk of developing major thrombotic or 
hemorrhagic complications. In patients younger than 60 years carrying only reversible or controllable 
cardiovascular risk factors, and without prior history of thrombosis, phlebotomy (PHL) and low dose aspirin 
are recommended. Cytoreductive therapy with either hydroxyurea (HU), a ribonucleotide reductase inhibitor 
considered non mutagenic, or Interferon-alfa (IFN) are appropriate first line drugs to prevent vascular 
complications in high risk patients (age >60 y and/or prior thrombosis)1. 
     HU was recommended in the treatment of high risk PV based on the results of PVSG protocol 08 in 
which this drug was found to be effective in reducing the rate of thrombotic events in 51 patients compared 
to an historical controls treated with PHL alone2. Very few studies were designed to confirm these 
conclusions. Recently, a propensity score analysis of patients enrolled in the ECLAP trial documented 
superiority of HU in reducing thrombosis compared with well-matched control patients treated with PHL 
only3. In three recent randomized controlled trials (RCT) in PV4–6, HU was compared to IFN; unfortunately, 
primary end-point was not the reduction of vascular complications but included only hematological response, 
that cannot be considered a surrogate of vascular events7. The only demonstration of an antithrombotic 
efficacy results from 2 RCT in essential thrombocythemia (ET) in which the drug was superior to 
chemotherapy-free and to anagrelide control arms8,9. Hence, the lack of solid demonstration of thrombosis 
prevention or survival advantage in PV and the concern that HU may increase the risk of leukemia led to an 
underuse of this drug in clinical practice10 and to suggest that the first line cytoreductive therapy in PV 
should be PHL only, irrespective of patient risk category11. 
However, even in the absence of clear demonstration of benefit, there is a consensus among ELN and NCCN 
experts of HU use in high risk cases and the drug is currently the first-line therapy in clinical practice. We 
have now several observational studies reporting single or multicenter experience regarding the risk-
estimates of clinical events associated with HU so that we deemed useful to provide a summary of these 
results in order to help clinical decision making and to offer estimates for a more realistic sample calculation 
in future comparative clinical trials. To answer this unmet knowledge need a great effort of data retrieval and 
analysis is necessary. Based on these premises, we carried out a literature review aimed at systematically 
assess and meta-analyze the incidence rate and absolute risk of events in patients treated with HU.  
Methods 
Inclusion criteria 
The protocol of the original review was registered in PROSPERO (number CRD4201811781412). 
Inclusion criteria were: 
1) Studies in English published in the last ten years (2008-2018) using WHO diagnostic criteria for PV.  
2) Studies on adult (aged ≥18) non-pregnant patients. 
3) Randomized Clinical Trials (RCTs), prospective and retrospective cohort studies reporting frequency 
of outcomes of interests (thrombotic and/or hemorrhagic events and/or hematological 
transformations in adult patients) stratified by Hydroxyurea therapy, as reported by authors. 
4) Studies with at least 20 participants. 
The following studies were excluded: case reports, cross-sectional studies, editorials, and narrative reviews. 
Studies aimed specifically at HU resistant patients were excluded. 
In case of duplicate studies on the same sample, the most numerous, or most informative, or most recent 
study was taken was taken into consideration. Studies not reporting follow-up duration were excluded. 
Search strategy 
We searched for articles or abstracts published between 2008 and 2018 in the following database: Medline, 
EMBASE, clinicaltrials.gov, WHO International Clinical Trials Registry (for unpublished or ongoing trials), 
LILACS. 
Terms used in research for primary endpoints were polycythemia vera, hydroxyurea/hydroxycarbamide, 
thrombosis, myelofibrosis. Research was focused on primary outcomes, although we also collected data on 
secondary outcomes (survival, leukemia, bleeding). Whenever possible, specific filters were used to exclude 
case reports, reviews, animal studies and studies on very young patients (aged < 18) or pregnant women. 
Conference abstracts and posters reporting relevant data were not excluded from consideration. Duplicate 
records were individually checked and merged using reference managing software.  
Data extraction 
The following data were extracted from selected studies: 
Type of study, mean (or median) follow-up duration, number of HU treated patients in the study, incidence 
of myelofibrotic and/or leukemic transformations, number of patients with at least 1 incident or recurrent 
episode of thrombosis or 1 bleeding, mortality, median/mean age, gender of patients, number of patients with 
cardiovascular risk factors, number of patients with history of thrombosis, number of patients undergoing 
antiplatelet or anticoagulant therapy. Whenever possible, number of patients with major arterial or venous 
thrombosis was extracted as well.  
Quality assessment 
Quality assessment of eligible studies was performed independently by two reviewers (T.B. and A.F.) 
according to the Joanna Briggs Institute Critical appraisal tool for studies reporting prevalence data13. The 
tool evaluates methodological quality of studies according to a 9-objects scale accounting for 
representativeness of the sample, accuracy of reporting, adequacy of diagnostic criteria and statistical 
analysis. 
Statistical analysis 
Incidence of each outcome was calculated and is reported as number of event per 100 persons/year. Forest 
plots show punctual estimates with exact binomial 95% confidence intervals for each study and globally. 
Persons/year were estimated by multiplying mean follow-up duration by number of HU treated patients; 
when mean follow-up duration was not available, median duration was deemed to be a reasonable 
approximation.  
In order to obtain global adjusted incidence estimates a logistic Generalized Linear Mixed Model (GLMM) 
was used for meta-regression of outcomes on study-specific confounders. The model included follow-up 
duration and known risk factors for the outcome as fixed effects; the random component of the model 
included a random slope for follow-up duration in studies. The method assumes that probability of 
displaying the event at time zero is the same across the studies, but it increases as a function of follow-up 
duration at a study-specific rate under the effect of selected covariates. The advantage of this model is that it 
uses an exact binomial likelihood and error structure and naturally accounts for heterogeneity in sample 
sizes14–16. For meta-regression, missing data about confounders were imputed to the sample size-weighted 
mean of the other studies. For reasons of interpretability and estimability of the model, predictor variables 
were all centered on their weighted mean. Intraclass Correlation Coefficients (ICC) were calculated 
conditional on fixed effects = 0 (i.e. the mean) and reported as heterogeneity measure.  
To evaluate whether results could depend on model choice, a sensitivity analysis was conducted by fitting a 
negative-binomial regression on events count, with persons/year as exposure variable. As opposed to the 
GLMM, such a model assigns the same weight to each study regardless of sample size and assumes a 
constant yearly event rate with no upper bound. 
Results 
Literature search and study characteristics 
The study selection process is detailed in Fig. 1.  
The search on Medline and EMBASE retrieved a total 420 results; 9 additional results were retrieved from 
different sources (clinicaltrials.gov, Cochrane Central Register of Controlled Trials, WHO International 
Clinical Trials Registry, references from relevant articles) for a total 429 results, which were reduced to 340 
after duplicates removal. Abstract and full-text screening allowed for the exclusion of 291 articles, as they 
fell into the following categories: reviews, case reports, animal studies, patients aged less than 18 or in 
pregnancy. Other studies were not considered as they had a total sample size of less than 20 patients, and/or 
they did not report incidence data or follow-up duration.  
Consequently, a total 49 studies were selected for methodological evaluation. 33 were excluded for the 
following reasons: 11 had unclear reporting of data (e.g. it was impossible to distinguish data due to HU-
treated patients from those due to other cytoreductive treatments, or PV from other myeloproliferative 
neoplasms); 7 did not meet the number of 20 HU treated patients as required by our study protocol; 7 studies 
referred to cases diagnosed outside the time window (2008-2018) and not with WHO 2008-2016 criteria; 1 
missed follow-up data, 1 was specifically aimed at HU resistant patients. In case of multiple studies from the 
same author(s), we inquired whether they referred to overlapping populations, by questioning authors when 
necessary, and excluded duplicates (6 studies) from review. The final selection comprised 14 full text articles 
and 2 conference abstracts to be included in the meta-analysis.  
Table 1 summarizes the main characteristics of the 16 eligible articles and abstracts. The selection included 3 
reports on 2 RCTs4,17,18 (one comparing HU and Interferon therapy and one HU to Ruxolitinib), 1 RCT 
where HU was not a comparator19 and 12 observational retrospective cohort studies7,20,29–33,21–28. The great 
majority of the studies were conducted in Europe and some involved multiple countries; only one study in 
our selection32 was conducted in the US. 
Number of HU treated patients ranged from 25 to 890 across studies; the final meta-analysis was conducted 
on a total of 3,236 patients in whom HU therapy was consistently administered. Follow-up duration ranged 
from 0·3 to 12·4 years.  
Quality of studies was judged using the JBI critical appraisal tool for prevalence studies considering sample 
size, representativeness of the sample, sampling methods, objectively measured outcomes, and adequate 
information on follow-up duration and potential confounders.  
Only two studies in our review, both by Alvarez-Larràn et al.7,21, were specifically aimed at obtaining 
incidence estimates under HU treatment, and thus fully met these criteria. The other studies, not addressing 
the same specific question about outcomes of HU treatment, often missed some of the above information; the 
most frequent issue was lack of stratification by HU treatment. For 6 of these studies, we readily had access 
to original databases, allowing us to fully extract data about HU treatment, outcomes and potential 
confounders. We were unable to retrieve full information from 2 additional reports4,29, but we could extract 
incidence of at least one of the outcomes of interest regardless. In 8 studies we were able to univocally 
distinguish arterial and thrombotic events in 2,048 patients7,19,23,26–28,31,33. 
Overall, demographics were incomplete or not stratified by HU treatment (6 studies); cardiovascular risk 
factors were missing (10 studies), and history of thrombosis was not reported (6 studies); antithrombotic 
drug therapy was not mentioned in 10 studies. However, in spite of missing data, in each of these studies we 
could retrieve the number of events for at least one outcome.  
Two studies referred to the same population 4,17, but reported different outcomes, therefore we did not 
consider it as a duplicate for the aims of our analysis.  
While most studies pertained to events after first line therapy, 3 focused on recurrent thromboses. 
 
HU and risk of outcomes 
Summary of events 
Figure 2 shows forest plots of the study-specific and pooled yearly incidence of each outcome of interest as 
% person/years with 95% binomial CI.  
The incidence of outcomes shows remarkable variability across studies. In particular, with the exception of 
AML, for the other outcomes 95% confidence intervals do not always overlap between studies.  
A mixed effect logistic model was applied to the data in order to obtain incidence estimates adjusted for 
heterogeneity and study-specific confounders, including follow-up duration. Confounding effects that were 
controlled for in meta-regression were age (for all outcomes), percent of patients under 
antiplatelet/anticoagulant therapy (for mortality and thrombosis), percent of patients with history of 
thrombosis (mortality, thrombosis), percent of patients with cardiovascular risk factors (mortality, 
thrombosis). Overall, regression analysis of MF and AML was only adjusted for age. Results from logistic 
regression are detailed in Supplementary Table 1. Diagnostics of model fit were performed by visual 
inspection of observed vs. fitted plots (Supplementary Figure 1).  
Fig. 3 shows probability of each outcome in follow-up as predicted by regression models when all 
confounders are kept fixed at their weighted mean value, with estimated ICC and relative statistical tests of 
heterogeneity. Since all predictor variables were centered on the mean, predictions are to be interpreted as 
incidence in the presence of confounding factors equal to the (weighted) mean. 
Event heterogeneity and timing 
No evidence of excess heterogeneity was found in meta-regression for MF (P=0·281) and AML (P=1·000) 
once adjusted for potential confounders, as opposed to mortality and thrombosis, where a small but non-zero 
amount of heterogeneity was observed despite adjustment. The distribution of events during follow-up as 
carried out by meta-regression highlighted a significant effect of age on probability of MF and thrombosis 
(and obviously on mortality), but not of AML (Fig. 2 and Suppl. Table 1). This effect is particularly strong 
for thrombosis. Remarkably, history of thrombosis was not a significant predictor of thrombosis risk in meta-
regression. 
A logistic model allows for incidence rates to change over time. To confirm that our results do not heavily 
depend on this assumption, we carried out a sensitivity analysis comparing the logistic GLMM to a negative 
binomial regression. In a negative binomial regression, yearly incidence is assumed constant over time. 
Results from the two models were fundamentally in agreement for thrombosis and AML outcomes, whereas 
for MF and overall mortality they started diverging after 5-years of follow-up. This indicates that, for 
practical purposes, thrombosis incidence rate can be assumed to be constant over time, at least up to a 10-
years observation period.  
Thrombosis incidence 
Adjusted estimates for annual incidence of thrombosis are reported in Table 2, globally and stratified by 
median age and previous thrombosis. Average incidence rate was 3·3% persons/year, ranging from 1·9% at 
60 years with no history of thrombosis to 6·8% at a median age of 80 years. Estimates increase with median 
age and are higher in presence of history of thrombosis, but the latter difference is not statistically 
significant. On the other hand, in a sub-analysis on arterial and venous thrombotic events, previous 
thrombosis was a highly significant (P<0·001) predictor of incidence of arterial thrombosis, but not of 
venous.  
Hematological transformations and mortality 
Of note, incidence of MF and overall mortality increases steeply after 5 years of follow-up according to the 
logistic GLMM. Estimates of myelofibrosis risk at a median age of 68 years are 0·9%, 5·0% and 33·7% at 1, 
5 and 10 years respectively, whereas mortality under the same conditions was 2·4%, 12·6% and 56·2%, but 
these estimates increase or decrease with age at the start of follow-up. Specifically, the odds of MF 
transformation increase on average 6% (95% CI 1-11%) for each year of age, while those of mortality 
increase by 21% (95% CI 9-33%). 
AML evolution, on the other hand, showed a stable incidence over time. According to the negative binomial 
model the annual rate of AML transformation was 0·4%, although the logistic model suggests a slight 
tendency to increase after about 8 years.  
Bleeding 
The number of major bleedings was deemed too small for reliable inference. Based on 88 events over 1,485 
patients, bleeding pooled incidence was 1% per year, independently of follow-up duration and 
antithrombotic therapy, as shown by meta-regression. This estimate was quite consistent, since no evidence 
of study heterogeneity was found for this outcome, but the small sample size may limit accurate detection of 
these effects.      
Second cancer and side effects 
The number of second cancers was too small, and between-study heterogeneity too high to allow for reliable 
inference on this outcome. Based on 59 events on 755 patients, pooled incidence of second cancer was 1.7% 
persons/year (95% CI 1.3-2.2%), mainly comprising non-melanoma skin cancer.   
Only two studies in our selection reported HU-associated adverse events, which does not allow to produce 
reliable estimates.  
Discussion 
(i) Summary of results 
We systematically collected literature on the benefit-risk profile of HU treatment in patients diagnosed with 
PV published in the 2008-2018 period. Out of 429 records, we selected 16 reports which allowed retrieval of 
incidence of specific clinical outcomes in these patients: namely major thrombosis, bleeding, evolution into 
MF and/or AML, mortality.  
Thrombosis 
In previous studies the incidence of thrombosis in high-risk PV patients candidates to cytoreductive 
treatment has been estimated from large patient cohorts including either patients under HU and patients not 
receiving cytoreduction or taking drugs other than HU34,35, so that the effect of HU was not clearly 
evidenced.   Overall thrombosis incidence in our population was about 3% per year, obtained by pooling 
together event rates from each study. This estimate does not account for heterogeneity across studies, yet a 
meta-regression analysis accounting for study-specific confounders such as median age, antithrombotic 
therapy, CV risk factors and history of thrombosis provides a slightly lower estimate of 2·8%. This rate does 
not seem to change over follow-up time, as shown by a comparison between a logistic and a negative 
binomial model, and depends on age. Based on 2,552 patients and 469 events, estimates of thrombosis 
incidence rate, in patients with a median age of 60, 70 and 80 years under HU treatment are 1·6%, 3·6% and 
6·8% respectively. 
Contrary to what is widely known, we did not find a statistically significant effect of history of thrombosis 
on incidence of new vascular events. Yet, this is not surprising in meta-regression analysis, since it is prone 
to the “ecological bias”, i.e. the loss of information that follows from dealing with aggregate data36. 
This mirrors the effect of increasing age on the thrombotic risk of the general population observed either for 
arterial and thrombotic events37,38; however, we highlight that the residual incidence of thrombosis in HU 
treated PV patients is still elevated, corresponding to approximately 10-fold higher than the one estimated in 
the general population37. It is therefore advised to promote new pharmacological strategies and to consider 
our reported thrombosis rate as a benchmark for future comparative studies.  
Hematological transformations, mortality and second cancer 
In regard to hematological transformations, we observed that AML annual incidence is fairly constant and 
the cumulative 10-year incidence is about 4% (0·4% patients/year).  
In contrast, annual incidence of evolution into MF, as predicted by meta-regression, increases steeply after 5 
years of follow-up. Therefore, in the 0-5/5-10 years of observation periods the average annual rate of MF 
evolution was 1·0% and 5·7% respectively. 
Mortality followed a similar pattern as MF, although divergence of the two meta-regression models was 
much less remarkable, with 95% CI overlapping. 
The incidence of second cancer we retrieved was 1.7% patients per year. However, the reliability of this 
estimate is dubious because of the limited number of events and the very large between-study heterogeneity 
for this outcome.  
(ii) Strengths and limitations 
The first major strength of our work is the remarkable sample size we were able to achieve, which allowed 
us to obtain robust estimates for the most relevant outcomes in PV.  
However, a possible limitation of our analysis is that most reports did not specifically address our study 
questions, and consequently the relative estimates are based on raw frequency data extracted from 
descriptive tables or text. Furthermore, we cannot exclude bias in reporting events in individual studies, since 
most of these were not specifically designed to answer our primary questions. On the other hand, the fact that 
the studies did not address our question makes publication bias in favor of certain results very unlikely.    
A second strength of our approach is that we managed to greatly reduce the issue of study heterogeneity by 
using adequate statistical methods, namely a logistic GLMM. In this way we mitigated the distortion due to 
this factor. Furthermore, by adjusting for study-specific covariates, we were able to account for the effect of 
the most relevant confounders, which for some outcomes (namely MF and AML) allowed us to reduce 
heterogeneity to negligible values. Of note, for most studies we were able to extract data on study-specific 
confounders stratified by treatment; this is expected to greatly reduce the effect of “ecologic bias, which is a 
common issue in meta-analysis of aggregated data. A limitation is that while our methods supposedly reduce 
ecological bias, it is likely impossible to entirely remove its effect in a meta-regression on aggregate data. 
Some known predictors of clinical outcomes, such as history of thrombosis, which is a well-known risk 
factor for recurrences, turned out to be not-significant in meta-regression. This may suggest that under HU 
treatment history of thrombosis is not a risk factor for recurrences anymore; but it may also be a byproduct of 
using aggregate data as predictors, with subsequent loss of information on individual patients36. 
A third strength is that by extracting data on follow-up duration and integrating them in the analysis we were 
able to model the time dependent evolution of outcome risk, thus overcoming a common bias in meta-
analysis of binary outcomes that is lack of temporal information. A potential source of bias in this respect is 
our choice to use median follow-up time when mean was not available, which can lead to biased risk 
estimates when the actual distribution of follow-up times in the study is very skewed. Yet, using the median 
as an estimator of mean has been shown to be reliable in most cases39.  
(iii) Conclusions 
This meta-analysis provides reliable risk estimates for thrombosis, hemorrhage, evolution to MF and AML, 
and mortality in PV patients under standard treatment with HU. This can be a valid reference for clinician, it 
can support patient communication and counseling, and also constitutes a help for sample size calculations in 
future comparative clinical trials by providing a reference value. We also prove the feasibility of clinical 
trials adopting hard efficacy endpoints such as frequency of cardiovascular events in selected populations. 
Lastly, we underline the value of an old, cheap, and safe molecule as a reliable and accessible resource for 
those settings where there is need to reconcile economic sustainability with the right to a quali-quantitative 
life advantage. 
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 Table 1: summary of study characteristics           
Study N FUP years Median age (range) Sex (M/F) Mortality MF AML Thrombosis Bleeding Study quality2 
Alvarez-Larrán, A. et al.(2012) 261 7·2 64 (16-88) 118/143 48 20 8 45 23 9/9 
Alvarez-Larrán, A., Kerguelen, A., et al.(2016) 890 4·6 68 (18-95) 452/438 99 39 17 71 48 9/9 
Barbui, T. et al.(2014) 137 7·7 60.5 (23-83) 69/68 16 12 3 21  8/9 
Bonicelli, G. et al.(2013) 114 11     7   6/9 
Crisa, E. et al.(2017) 35 6·3 55 (36-65) 23/12 3 3 2 3  8/9 
De Stefano, V. et al. (1)(2016) 34 5·1 51.5 (19-80) 10/24 3 2 1 10 5 8/9 
De Stefano, V. et al. (2)(2016) 45 7 71.5 (46-90) 24 / 21 3 6 1 7 1 8/9 
De Stefano, V. et al.(2018) 104 3·7 73 (43-95) 46/58 16 2 2 18  8/9 
Gisslinger, H. et al.(2016) 127 1 60 (21-81) 60/67 0 0 0 2  5/8 (1) 
Gisslinger, H. et al.(2017) 73 2·7   0 0 2   5/8 (1) 
Hintermair, S. et al.(2018) 25 8      7 2 8/9 
Lussana, F. et al.(2014) 46 12·4 35.8 (22-40) 22/24 3 6 1 19 6 8/9 
Marchioli, R. et al.(2013) 184 2·4 71 (44-87) 108/76 6 3 1 16 3 8/9 
Mesa, R. et al.(2017) 56 0·3 66 (19-85) 34/22 1 0 0 2  6/7 (2) 
Podoltsev, N. A. et al.(2018) 497 2·83 77  173   118  8/9 
Tefferi, A. et al.(2013) 608 6·9 63.3 (19-95) 296/312 151 64 18 130  8/9 
           
Total 3,236 . 68·41  522/3,097 157/2,600 63/2,714 469/2,552 88/1,485  
1 Weighted mean 
2
 Evaluation on 9 items according to JBI appraisal tool for prevalence studies. In parenthesis number of items for which evaluation was not applicable based on study design. 
 
 
 Table 2: Thrombosis incidence by age and history of thrombosis 
  Age 
 Average 60 years 70 years 80 years 
 
Risk 95% CI Risk 95% CI Risk 95% CI Risk 95% CI 
Average 3·3% 2·2 4·4 1·9% 0·7 3·2 3·6% 2·4 4·8 6·8% 2·6 11·1 
No prev. Thrombosis 3·0% 1·3 4·6 1·8% 0·3 3·2 3·3% 1·5 5·0 6·1% 2·0 10·2 
Prev. Thrombosis 4·5% 1·1 7·9 2·7% 0·6 4·7 5·0% 1·0 8·9 9·3% 0·0 19·7 
 [Captions] 
Figure 1: Study flowchart 
 
Figure 2: Forest plot of outcomes incidences. The incidence is not graphed for Mesa et al. since its very large CI 
couldn’t fit in the plot, but is accounted for in global estimates. Size of markers annotates study sample size. 
 
Figure 3: outcomes incidence during follow-up according to logistic GLMM (Generalized Linear Mixed Model) and 
comparison with negative-binomial model. Dashed lines are 95% CIs, observed frequencies are plotted in hollow 
circles of size proportional to sample size in person/years. ICCs (Intracluster Correlation Coefficients) and p-values of 
Likelihood Ratio Tests of random slopes are reported 



Supplementary tables and figures 
 
Supplementary Table 1: Logistic models – fixed effects estimates 
    
 OR P-value 95% CI 
Mortality    
Follow-up duration 1·55 0·007** 1·12,2·13 
Age 1·21 0·000*** 1·09,1·33 
Antiplatelet 3·93 0·547 0·05,338·10 
Anticoagulant 1·16 0·861 0·22,6·02 
CV risk 0·00 0·192 0·00,20·48 
Previous thrombosis 1·04 0·968 0·15,7·12 
    
    
MF    
Follow-up duration 1·55 0·000*** 1·31,1·83 
Age 1·06 0·021* 1·01,1·11 
    
    
AML    
Follow-up duration 1·21 0·001*** 1·08,1·36 
Age 1·02 0·336 0·98,1·07 
    
    
Thrombosis    
Follow-up duration 1·20 0·016* 1·03,1·39 
Age 1·13 0·000*** 1·08,1·19 
Antiplatelet 5·30 0·156 0·53,53·06 
Anticoagulant 1·51 0·323 0·67,3·42 
CV risk 0·00 0·001*** 0·00,0·04 
Previous thrombosis 2·08 0·174 0·72,5·99 
Exponentiated coefficients 
* p < 0.05, ** p < 0.01, *** p < 0.001 
 Supplementary Figure 1: observed vs fitted plots of logistic GLMM for each outcome. Circle sizes are weighted by study dimension. Predicted values are in good agreement with 
observed events. 
